Alexion to present Phase III HICKORY data for efzimfotase alfa at ASBMR 2026
AZN•AstraZeneca’s Alexion unit scheduled 16 presentations for the ASBMR meeting in Boston on Oct. 9-12, 2026, including future presentation of Phase III HICKORY results for efzimfotase alfa in adolescent and adult hypophosphatasia.
1. ASBMR presentations
Alexion scheduled 16 presentations for the ASBMR meeting in Boston on Oct. 9-12, 2026. Phase III HICKORY results for efzimfotase alfa in adolescent and adult hypophosphatasia are to be presented; Phase III CALYPSO skeletal findings for eneboparatide in chronic hypoparathyroidism are also scheduled for future presentation.
2. Potential treatment impact
The HICKORY data are positioned to support broader use in adult-onset disease, potentially reshaping care expectations while aiming to reduce treatment burden.
